REP 2139

Drug Profile

REP 2139

Alternative Names: REP 2139; REP 2139 calcium chelate; REP 2139 magnesium chelate; REP 2139-Ca; REP 2139-Mg; REP 9AC'

Latest Information Update: 27 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator REPLICor
  • Class Antivirals; Nucleic acids; Oligonucleotides; Polymers
  • Mechanism of Action Hepatitis B virus replication inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis B; Hepatitis D

Most Recent Events

  • 20 Dec 2017 Pharmacodynamics data from a preclinical study in Hepatitis B infection released by Replicor
  • 23 Oct 2017 Interim efficacy data from a phase IIb REP 401 trial in hepatitis B released by Replicor
  • 12 Jun 2017 Pharmacokinetics and safety data from a preclinical trials in Hepatitis B released by Replicor
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top